Nathan Wood, Chief Executive Officer

Nathan Wood is the CEO and Board Member of KromaTiD. Nathan has nearly 30 years of proven experience in the life sciences industry.  He has held leadership roles in sales, marketing, product development and management at several companies in the genomics and life sciences industries, including Life Technologies Corporation and QIAGEN Inc. Nathan served on BIOCOM’s Renewables Advisory Board. He has also served on the Board of Directors of GeneArt, Blue Heron, SB Biofuels and the College of Science at Oregon State University.

Most recently, Nathan served as CEO at Swift Biosciences. Under his leadership, Swift grew quickly by effectively leveraging new products and marketing strategies. Additionally, Nathan’s experience—across European and American multinational companies—spans strategic planning, financial performance measurement and global business strategy.

Christopher Tompkins Ph.D., Chief Technology Officer

In addition to being the Chief Technology Officer, Chris Tompkins is a member of the Board of Directors. He has twenty years of pharmaceutical and biotechnology industry experience focused in the areas of process development, operations and the commercialization of new technologies. Dr. Tompkins past experience includes COO at Evia Medical, Vice President of Operations and Chief Compliance Officer at Atrius Bioscience, General Manager of Proligo LLC, and other executive roles at Proligo. Dr. Tompkins has also lead projects and performed engineering development for two marketed pharmaceutical products; at NeXstar Pharmaceuticals, he led the development team and designed the reactor technology for the macular degeneration treatment, Macugen™; and at Hoffmann-La Roche he was jointly responsible for the development and scale-up of the 5-FU pro-drug Xeloda™.  Dr. Tompkins graduated with a Bachelor of Science degree in Chemical Engineering from the University of Michigan and a Ph.D. in Chemical Engineering from North Carolina State University.

Gretchen Pratt, Sr. Director of Operations

Prior to joining KromaTiD, Ms. Pratt spent 9 years at Amgen in a variety of roles within Operations, including manufacturing, engineering, project management, and risk management. She has previous roles as Operations Manager at AlloSource, and Sr. Manager Primers & Probes at Proligo. Ms. Pratt has a B.A. in Chemistry from Kalamazoo College, M.S. in Chemical Engineering from the University of Virginia, and is a Certified Lean Six Sigma Green Belt (ASQ).

Gordon H. Link Jr., Chief Financial Officer

Mr. Link joined KromaTiD in 2018. After seven years in public accounting he served an additional 25 years in a variety of senior executive and senior financial roles in public and private biotech companies. Most recently Mr. Link served six years as the Chief Financial Officer of Newlink Genetics Corporation, completing a variety of financings including the Company’s Initial Public Offering. Previously, Mr. Link worked for Tapestry Pharmaceuticals, Inc., directing a staff of five to ten individuals in areas of accounting, risk management, financial reporting and investor relations. Mr. Link also worked with Tapestry’s Board of Directors to coordinate Tapestry’s initial public offering and subsequent follow-on public offerings of common stock. Prior to joining Tapestry, Mr. Link served as Corporate Controller of Synergen, Inc., Treasurer of the Syntex-Synergen Neuroscience Joint Venture, Treasurer of Synergen Development Corporation and Audit Manager with Deloitte & Touche USA LLP. Mr. Link received a B.S. degree in Chemistry from Rensselaer Polytechnic Institute and a B.A. degree in Accounting from Metropolitan State University

Board of Directors

Terry Opgenorth, Ph.D.

Serves as the Chairman of the Board of Directors. Dr. Opgenorth previously worked for Abbott Laboratories (now AbbVie) as Divisional Vice President of Metabolic Disease Research, Antiviral (HCV) Research and Target-Lead Discovery Research for Abbott’s Global Pharmaceutical Research and Development division. He also served as President and CEO of Vidasym for 6 years, a company developing drugs for human chronic kidney disease. Terry holds a number of current positions, including Vice President for CSU Ventures and Executive Director of LAUNCHPAD, CSO/Founder of VetDC, a veterinary oncology company, and Board of Directors for VetDC, UNeMed, PhotonPharma, and Laporte Therapeutics.  Dr. Opgenorth holds a B.A. in Biology from Calvin College and M.S. and Ph.D. degrees in Physiology from University of Illinois-Urbana.

James E. Chomas, Ph.D.

Dr. Chomas joined KromaTiD in 2021 and brings a track record of success in developing and commercializing novel healthcare products.  Jim currently serves as CEO of CereHealth, a medical analytics company focused on brain health.  Prior to CereHealth, Jim founded and led Surefire Medical (now TriSalus Life Sciences), an innovative oncology therapeutics and drug delivery company, from initial patents through successful worldwide commercialization.  Jim also served in leadership roles at Cabochon (acquired by Ulthera) and Siemens.  He has authored over 40 patents in medical technology and serves as an advisor to multiple healthcare startups in the Colorado bioscience ecosystem.

Jim holds a dual B.S.E in electrical and biomedical engineering from Duke University and a PhD from U. Virginia

Joel Bedford, Ph.D.

Dr. Bedford joined KromaTiD as a founder of the company in 2007, chairs the Scientific Advisory Board and is a member of the Board of Directors. Dr. Bedford is currently a Professor in the Department of Environmental and Radiological Health Sciences at Colorado State Universtiy and holds a joint faculty appointment in the University Graduate Program in Cell and Molecular Biology. His programs have been funded by NIH, DOE and NASA since 1966. He has served as a regular member and Chairperson of the NIH Radiation Study Section, as a Counselor, Associate Editor, and later as President of the Radiation Research Society. He has received various awards such as the Failla Award and the Excellence in Mentoring Award from the Radiation Research Society. He has been a regular member of the National Academies’ Board on Radiation Effects Research, and then on the National Academies’ Nuclear and Radiation Studies Board. He served a 5-year term on the Scientific Council of the Radiation Effects Research Foundation in Hiroshima, Japan, and is a member of the National Council on Radiation Protection and Measurements. Professor Bedford has authored 140 peer-reviewed articles, including several book chapters, and is an inventor on two patent applications. Professor Bedford received his B.A. degree in Chemistry from the University of Colorado, an M.S. degree in Radiology from the University of Colorado Medical School, and Doctor of Philosophy Degree in Radiobiology from Oxford University.

David Brunel

Mr. Brunel joined the KromaTiD Board in 2019 with 19 years of experience in molecular diagnostics and over 20 years of experience in enterprise software.  Mr. Brunel currently serves as Chief Executive Officer and Director at Biodesix, a company that develops and commercializes non-invasive blood-based molecular diagnostic tests for oncology. Effective January 1st, 2020, Mr. Brunel will transition from CEO to Chairman of Biodesix.

Ginny Orndorff

Ginny Orndoff joined the KromaTiD board in 2015. She is the Executive Director of the Colorado Institute for Drug, Device, and Diagnostic Development (CID4) and acting CEO of SixOne Solutions, LLC, and Claudin Technologies. Ginny co-founded Evolutionary Genomics of Longmont, CO and was its CEO for 10 years, continuing today on its board of directors. Prior to that, she was CEO of GenoPlex of Denver, CO; Director of Technology/Business Development for NeXstar of Boulder, CO; and Director of Biotechnology Programs at the Colorado Advanced Technology Institute. She has a B.A. in Biology from the University of California Santa Cruz, an M.A. in Microbiology from California State University San Jose, and an M.B.A from Loyola College.